Please assess the completion status of the following clinical trial:

Trial Title: A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion criteria:~* Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.~* Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome of (9:22) translocations~Key Exclusion criteria:~* Previously documented T315I mutation~* Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib~* Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide~* Impaired cardiac function.~* Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).~* Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)~* Currently receiving treatment with any medications that have the potential to prolong the QT interval.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nilotinib 300mg bid (investigating arm) (Type: EXPERIMENTAL): None
- Nilotinb 400 mg bid (investigating arm) (Type: EXPERIMENTAL): None
- imatinib 400mg QD (control arm) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).